Methylphenidate ER tablets (10 mg, 20 mg)

METHYLPHENIDATES · EXTENDED-RELEASE TABLET (RITALIN-SR TYPE) · GENERIC

GENERIC ONLY RITALIN-SR BRAND DISCONTINUED MARKETED (DAILYMED SPLs) SOME SUPPLIERS BACK-ORDERED (ASHP)
STIMULANT · SCHEDULE II · REVIEWED NOV 2026
Reviewed by Tariq Halim, MD — ABPN Board-Certified General Psychiatrist · Editorial policy
Last medical review: November 12, 2026
Tariq Halim, MD reports no conflicts of interest. Contact

Key facts

Drug class
CNS Stimulant · Methylphenidates
Active ingredient
methylphenidate hydrochloride
Approved uses
ADHD in children 6 years and older and adults; narcolepsy
Form and strengths
Extended-release tablet; 10 mg and 20 mg extended-release tablets (Alkem/Ascend: 20 mg only)
Usual dose and maximum (label)
Adults: 20 or 30 mg daily; maximum 60 mg/day. Children start on an immediate-release product first.
Duration
About 8 hours (label duration of action).
DEA schedule
Schedule II controlled substance (CII)
Generic
Generic only (see Generic manufacturers)
Label date
Prescribing Information revised 10/2025 (DailyMed)

Label last checked: Oct 2026 — Prescribing Information revised 10/2025 (DailyMed) · Last medical review: November 12, 2026

Educational information only, not medical advice. Do not start, stop or change a medication without your prescriber. Medical disclaimer

Methylphenidate ER tablets 10 mg and 20 mg are generic extended-release methylphenidate tablets of the older Ritalin-SR type. The label says they last about 8 hours, so they can replace an 8-hour total of immediate-release methylphenidate (for example, 10 mg twice daily can be replaced by one 20 mg ER tablet, if the doses match). They must be swallowed whole. The Ritalin-SR brand is discontinued, but AB-rated generics remain listed. They are not the same as Concerta or its 18–72 mg generics.

What it is

These tablets release methylphenidate more slowly than regular (immediate-release) tablets, so one dose covers about 8 hours, roughly a school day without a lunchtime dose for some people. They contain the same medicine as Ritalin. They come only as generics in 10 mg and 20 mg strengths and must be swallowed whole, never crushed or chewed.

Methylphenidate hydrochloride extended-release tablets 10 and 20 mg; indicated for ADHD in pediatric patients 6 years and older and adults, and narcolepsy (SpecGx label revised 10/2025). Per labeling the duration of action is approximately 8 hours, and they may be used in place of IR methylphenidate when the 8-hour ER dosage corresponds to the titrated 8-hour IR dosage. Relative bioavailability vs IR tablets 105% (children) and 101% (adults); time to peak rate in children 4.7 h (range 1.3–8.2) vs 1.9 h for IR. Schedule II. Orange Book (October 2026): reference listed drug Ritalin-SR (NDA 018029) DISCN; AB-rated ANDAs RX from SpecGx (listed as “Methylin ER”, 10 and 20 mg), Abhai (10 and 20 mg; 20 mg is the reference standard), Granules (10 and 20 mg) and Alkem (20 mg).

When considering this for a patient

The 10/20 mg ER tablets are an option when a single morning dose covering about 8 hours is enough, when the patient is already stable on twice-daily IR methylphenidate at a matching dose, or when cost and formulary favor an older generic. Because the effect is shorter than 12-hour products and release is single-phase, afternoon or evening coverage may need a separate plan.

They are not substitutable with Concerta-type osmotic tablets (18–72 mg), which have a different release design, strengths and Orange Book reference. Schedule II with a boxed warning for abuse; screen for cardiac disease before starting and monitor appetite, sleep, growth, blood pressure and heart rate.

Patient profile and niche

Methylphenidate ER 10/20 mg tablets may be particularly useful in the following situations:

  • Patients stable on twice-daily IR methylphenidate whose total 8-hour dose matches 10 or 20 mg (or multiples).
  • When about 8 hours of coverage from one morning dose is sufficient.
  • Cost-sensitive situations where an older generic extended-release tablet is preferred.
  • When Concerta-type ER tablets are hard to obtain and the clinician decides an 8-hour product is suitable (not an interchangeable substitute).

Less suited for patients who cannot swallow tablets whole, who need 10–12 or more hours of coverage, or who need a rapid early-morning onset (labeling does not include an immediate-release component). These are clinical considerations, not labeled restrictions.

When it is active

The label states a duration of action of about 8 hours. Blood levels rise more slowly than with regular tablets: in children, the time to peak was about 4.7 hours (range 1.3–8.2 hours) versus about 1.9 hours for immediate-release tablets. The label does not state when the effect begins.

Use the interactive tool below to align a morning dose with your day. The curve is a schematic based on labeling data, not a prediction for any individual.

YOUR DAY WITH ONE METHYLPHENIDATE ER (10/20 MG) TABLET

Enter the times that match your (or your child’s) typical day. The curve shows relative plasma level over clock time.

Typical single ER tablet dose · Peak near 4.7 hours (children) · Duration of action about 8 hours per label
The label does not state when the effect begins; the onset marker is a drawing convention, not a label value. The curve shows relative plasma concentration, not guaranteed clinical effect.
Swallow whole; never crush or chew. Everyone is different. This is a general guide based on labeling data, not a prediction for any one person.
Relative plasma level schematic for a single ER tablet dose (not to clinical scale). Labeling (SpecGx 10/2025; Granules 08/2026): duration of action approximately 8 h; time to peak rate in children 4.7 h (1.3–8.2 h) vs 1.9 h for IR; high-fat meal raised AUC 25% and Cmax 27% and shortened median Tmax (2.5 h fed vs 3 h fasted). The ER labels do not report a half-life; the curve uses the Ritalin-tablet half-life in children from the Ritalin LA label (12.3: about 2.5 h, range 1.5–5.0 h; adults about 3.5 h), matching the pediatric peak-time data. Because a one-compartment curve with a 2.5 h half-life cannot peak later than ~3.6 h, the schematic adds a 1.5 h absorption lag (a modeling device, not a label value) so the peak sits at 4.7 h. The label does not state when the effect begins; the 60-minute onset marker is a drawing convention for the chart, not a label value. Individual curves vary.

How it works

Schematic of methylphenidate mechanism: DAT and NET reuptake blockade
Methylphenidate blocks DAT and NET, reducing reuptake of dopamine and norepinephrine; labeling also describes increased release of these monoamines into the extraneuronal space.

Methylphenidate blocks the transporters that normally remove dopamine and norepinephrine from the synapse, so more of these neurotransmitters are available in brain areas involved in attention and impulse control. The ER tablet releases the medicine gradually, so one tablet works for about 8 hours instead of about 3–4.

DAT Dopamine transporter blockade
Increases synaptic dopamine
NET Norepinephrine transporter blockade
Increases synaptic norepinephrine
SINGLE-PHASE ER Gradual release
Peak about 4.7 h after the dose (children)
NOT OSMOTIC (OROS) Different design from Concerta
Not interchangeable

Per labeling, the mode of therapeutic action in ADHD is not known. Methylphenidate blocks the reuptake of norepinephrine and dopamine into the presynaptic neuron and increases the release of these monoamines into the extraneuronal space. Methylphenidate is racemic; the d-enantiomer is more active. Plasma protein binding is low (10–33%); it is metabolized mainly by de-esterification to ritalinic acid, and 78–97% of a dose is excreted in urine as metabolites. The SpecGx tablets list hydroxypropyl methylcellulose, magnesium stearate, microcrystalline cellulose and talc and are color-additive free; the labels do not describe an osmotic system or an immediate-release overcoat.

Formulations and duration

Generic extended-release tablets in two strengths, taken once (or as directed) and swallowed whole. These are an older design than Concerta-type ER tablets and are not interchangeable with them.

STRENGTHS10 mg and 20 mg extended-release tablets (Alkem/Ascend: 20 mg only)
APPROVED USESADHD in children 6 years and older and adults; narcolepsy
DURATION (LABEL)Approximately 8 hours
ADMINISTRATIONSwallow whole; never crush or chew
NOT THE SAME ASConcerta, Relexxii and their 18–72 mg methylphenidate ER tablet generics (osmotic-type, ~12 h)
BRANDRitalin-SR (Novartis, NDA 018029) — discontinued (Orange Book; Federal Register determination: not withdrawn for safety or effectiveness)

Appearance

All are white to off-white round tablets; imprints differ by manufacturer (DailyMed labels):

  • SpecGx (Mallinckrodt) — 10 mg “1423” and 20 mg “1451” on one side with a logo mark on the other (SPL imprint data: “M”) (NDC 0406-1445-01, 0406-1473-01)
  • KVK-Tech (ANDA 207488, Orange Book applicant Abhai) — 10 mg “K75”, 20 mg “K76”, plain reverse (NDC 10702-075, 10702-076)
  • Granules — 10 mg “FM4”, 20 mg “FM5”, plain reverse (NDC 70010-042, 70010-043)
  • Ascend (manufactured by Alkem) — 20 mg “MER” / “20” (NDC 67877-615-01)

Repackagers (for example Golden State Medical Supply) may list the same tablets under their own NDCs. Always check the bottle label for the manufacturer and strength.

Official package photos and pill identifiers:

Generic manufacturers

These tablets are available only as generics. The reference brand, Ritalin-SR, is discontinued. AB-rated generics are listed in the Orange Book (October 2026):

Orange Book applicant (DailyMed labeler)Notes
SpecGx LLC (SpecGx / Mallinckrodt)ANDA 075629, listed as “Methylin ER”; 10 and 20 mg; AB; DailyMed marketing start May 9, 2000; ASHP: on back order (active-ingredient shortage)
Abhai LLC (KVK-Tech)ANDA 207488; 10 and 20 mg; AB; 20 mg is the Orange Book reference standard; DailyMed marketing start Jun 9, 2015; ASHP: available
Granules (Granules Pharmaceuticals; also Golden State Medical Supply)ANDA 210992; 10 and 20 mg; AB; DailyMed marketing start Dec 17, 2018
Alkem Laboratories (Ascend Laboratories)ANDA 212288; 20 mg only; AB; DailyMed marketing start Oct 8, 2020
Ritalin-SR (Novartis)NDA 018029 — discontinued

Orange Book (October 2026): RX AB-rated ANDAs for methylphenidate HCl ER tablets 10/20 mg as above; Metadate ER (ANDA 089601) and several older ANDAs (Able, Alvogen, Heritage, Watson) are DISCN, although older Metadate ER SPLs remain on DailyMed. The 18–72 mg methylphenidate ER tablets (Concerta generics, AB or BX) are a different product group.

Common side effects

Side effects are those of methylphenidate in general. The ER tablet labels list (without frequencies) decreased appetite, trouble sleeping, anxiety, restlessness, headache, dizziness, stomach pain, nausea, dry mouth, fast heartbeat and increased blood pressure, among others:

EFFECTFREQUENCYNOTES
Decreased appetite / weight lossListed in label (frequency not stated)Weight and growth are checked
Trouble sleepingListed in labelTake in the morning; tell your clinician
Headache, dizzinessListed in labelUsually mild
Stomach ache, nausea, dry mouthListed in labelReport if persistent
Fast heartbeat, palpitations, higher blood pressureListed in labelBlood pressure and pulse are monitored
Anxiety, restlessness, agitationListed in labelTell your clinician if it persists

The SpecGx and Granules labels list adverse reactions from clinical trials, spontaneous reports and literature without frequencies (section 6). Boxed warning for abuse, misuse, and addiction; assess risk before prescribing and reassess during treatment. Warnings include risks to patients with serious cardiac disease, increased blood pressure and heart rate, psychiatric adverse reactions, priapism, peripheral vasculopathy including Raynaud’s phenomenon, long-term suppression of growth in pediatric patients, acute angle-closure glaucoma, increased intraocular pressure, and motor and verbal tics/worsening of Tourette’s syndrome. Contraindicated with MAOIs or within 14 days of stopping an MAOI, and in patients with hypersensitivity to methylphenidate. The SpecGx label (10/2025) carries the older boxed-warning title “Abuse and Dependence”; the Granules label (08/2026) uses the current “Abuse, Misuse, and Addiction” class wording and adds glaucoma and tic warnings.

Misuse context (outside the label): in SAMHSA’s 2023 National Survey on Drug Use and Health, 1.4% of people aged 12 or older (about 3.9 million) misused a prescription stimulant in the past year; the rate was highest in adults aged 18 to 25 (3.1%). The survey counts all prescription stimulants (amphetamine and methylphenidate products, weight-loss stimulants and others), not this medicine alone (SAMHSA, 2023 NSDUH).

Dosing considerations

Children usually start on regular (immediate-release) methylphenidate and are switched to the ER tablet once the right dose is found. Adults usually take 20–30 mg a day. The tablet is swallowed whole.

Granules label 2.2 (08/2026): pediatric patients 6 years and older — start with an IR methylphenidate product 5 mg twice daily, then switch to ER tablets 10 mg once daily; may increase gradually; maximum 60 mg/day. Adults — 20 or 30 mg daily; maximum 60 mg/day. SpecGx label 2.2: may be used in place of IR tablets when the 8-hour ER dosage corresponds to the titrated 8-hour IR dosage. If paradoxical worsening or other adverse reactions occur, reduce or discontinue; if no improvement after appropriate adjustment over one month, discontinue. Wait at least 14 days after stopping an MAOI. Before starting, assess cardiac history and, per current class labeling, mania risk and tics/Tourette’s.

Baseline ECG: The label’s pre-treatment cardiac assessment is a careful history, including family history of sudden death or ventricular arrhythmia, and a physical exam; it does not call for a routine ECG. NICE NG87 states that an ECG is not needed before starting stimulants unless a feature listed in 1.7.5 is present (e.g., congenital heart disease or previous cardiac surgery, sudden cardiac death in a first-degree relative under 40, exertional breathlessness or syncope, paroxysmal palpitations, cardiac-sounding chest pain, signs of heart failure, a murmur, or adult hypertension) or a co-existing condition is treated with a medicine that adds cardiac risk; those features call for a cardiology opinion (1.7.4–1.7.5). The AAP 2019 guideline asks for a history of cardiac symptoms and a family history of sudden death, WPW, hypertrophic cardiomyopathy and long QT, with further evaluation if any risk factor is present. A Canadian joint position statement (Warren 2009) and the European ADHD Guidelines Group (Graham 2011) do not recommend routine ECG screening; Graham notes that the American Heart Association’s 2008 statement first proposed an ECG as standard and then left it to clinician discretion. In one US screening series, 8.1% of ECGs were abnormal but heart disease was found in 0.3% (Mahle 2009).

Planned breaks from medicine (weekends and holidays)

Some families leave out doses on weekends or during school holidays. This is sometimes called a medication holiday or treatment break. Plan any break with the prescriber instead of stopping on your own.

Breaks are usually considered for poor appetite, slow weight gain, trouble sleeping, slowed growth, or to see whether the medicine is still needed. The label says children who are not growing or gaining weight as expected may need to have treatment paused.

In studies, breaks helped appetite, sleep and weight gain. It is less clear that they help a child end up taller: one older study saw a height benefit only after two summers off, and a newer trial found that weekend breaks did not speed up height growth. ADHD symptoms can return on days off, so breaks tend to suit lower-pressure times. If you try one, watch how things go at home and with friends, and restart if problems come back.

Growth warning (label 5.7): monitor height and weight during treatment of pediatric patients; those not growing or gaining height or weight as expected may need treatment interrupted. NICE NG87 lists a planned break among options when weight loss is a concern (1.8.6), suggests considering a break over school holidays to allow catch-up growth when height is significantly affected (1.8.7), and advises periodic trial periods off medication or at a lower dose when the balance of benefit and harm suggests it (1.10.3). The AACAP 2007 practice parameter suggests considering a holiday when height or weight crosses two percentile lines, provided off-medication weekends or summers are not markedly impairing, and regards low-stress periods such as vacations (not the start of a school year) as a good time for a discontinuation trial.

Evidence (see Clinical evidence: Growth, below): in a 4-week RCT of twice-daily IR methylphenidate, weekend placebo reduced insomnia without a significant rise in weekend parent or Monday teacher ratings (Martins 2004, n=40). In children with stimulant-associated weight loss, school-days-only dosing increased weight velocity but not height velocity, and most families in that arm resumed after-school dosing because of symptoms (Waxmonsky 2020). Two summers off methylphenidate were followed by a height benefit; one summer was not (Klein 1988). A review of 22 studies found 25–70% of families use breaks (Ibrahim 2015). In the observational MTA follow-up, consistent long-term use was associated with about 2.4 cm lower adult height (Swanson 2017). Data in adults are sparse.

Pregnancy and breastfeeding

Tell your clinician if you are pregnant, plan to become pregnant, or are breastfeeding. Studies of methylphenidate in pregnancy have not shown a higher risk of major birth defects or miscarriage. Stimulant medicines can narrow blood vessels, which may reduce blood flow to the placenta.

Outside the label: in one very large study of US and Nordic pregnancy records, methylphenidate taken in the first 3 months of pregnancy was linked to a possible small increase in heart defects, while the overall rate of birth defects was not significantly higher. Absolute risks stayed low. See Clinical evidence from published studies (Pregnancy) below.

Small amounts of methylphenidate pass into breast milk. No harm to breastfed babies and no effect on milk supply have been reported, but long-term effects are not known. If you breastfeed while taking methylphenidate ER tablets, decide together with your clinician, and watch the baby for agitation, poor sleep, poor feeding, or slow weight gain.

A national pregnancy registry collects information about ADHD medicines used during pregnancy. You or your clinician can enroll by calling 1-866-961-2388.

Pregnancy (label 8.1): published studies and postmarketing reports on methylphenidate in pregnancy have not identified a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. The label adds that there may be risks to the fetus from CNS stimulant use. Clinical considerations: CNS stimulants can cause vasoconstriction and thereby decrease placental perfusion; no fetal or neonatal adverse reactions have been reported with therapeutic doses of methylphenidate, but premature delivery and low birth weight have been reported in infants of amphetamine-dependent mothers. Animal data: no effects on fetal morphology in rats and rabbits at up to 10 and 15 times the adolescent maximum recommended human dose (MRHD); spina bifida in rabbits at about 52 times the MRHD; decreased pup weight in a rat pre- and postnatal study at about 6 times the MRHD. Registry: National Pregnancy Registry for ADHD Medications (as named in the label), 1-866-961-2388.

Lactation (label 8.2): limited published data (milk sampling from seven mothers) show methylphenidate in human milk at infant doses of 0.16% to 0.7% of the maternal weight-adjusted dose and a milk/plasma ratio of 1.1 to 2.7, with no reported adverse effects in breastfed infants and no effects on milk production; long-term neurodevelopmental effects are unknown. Weigh the benefits of breastfeeding against the mother’s clinical need for methylphenidate ER tablets and any potential effects on the infant. Monitor breastfed infants for agitation, insomnia, anorexia, and reduced weight gain.

Outside the label (InPreSS; Huybrechts 2018, JAMA Psychiatry; PubMed 29238795): first-trimester methylphenidate in a US Medicaid cohort of 1,813,894 pregnancies, adjusted RR for any congenital malformation 1.11 (95% CI 0.91–1.35), not significant; cardiac malformations 1.28 (0.94–1.74) in the US cohort and 1.28 (1.00–1.64) when pooled with a Nordic cohort of 2,560,069 pregnancies. Amphetamines showed no increase (any malformation 1.05, cardiac 0.96). These are observational findings; they do not change the label’s section 8.1 statement.

Outside the label: LactMed (NCBI Bookshelf, “Methylphenidate,” revised Aug 2025; NBK501310) says milk levels at prescribed doses appear very low and were not detectable in infant blood, that needing methylphenidate is not a reason to stop breastfeeding, and that large doses might reduce milk production, especially before lactation is well established. This is LactMed’s summary of published data, not FDA label content.

Availability and shortages

MARKETED · SOME BACK ORDERS These generic tablets are listed as marketed on DailyMed by several manufacturers. ASHP lists KVK-Tech 10 mg and 20 mg ER tablets as available and Mallinckrodt (SpecGx) 10 mg and 20 mg as on back order. Stock can vary by pharmacy.

If your pharmacy cannot fill your usual manufacturer, ask whether another AB-rated 10/20 mg ER tablet is in stock. Do not switch to a Concerta-type ER tablet or another product without talking to your clinician, because they are not mg-for-mg substitutes.

ASHP (Methylphenidate Extended Release Oral Presentations, updated Oct 14, 2026): KVK-Tech 10 and 20 mg ER tablets available; Mallinckrodt 10 and 20 mg ER tablets on back order (shortage of an active ingredient), no release date. FDA Drug Shortages (Methylphenidate Hydrochloride Tablet, Extended Release — Currently in Shortage) lists only 18–72 mg presentations, none at 10 or 20 mg. DailyMed SPLs with active marketing and no end date: SpecGx (eff. 10/2025), KVK-Tech (10/2025), Granules (08/2026), Ascend (09/2022). Current Granules and Alkem/Ascend stock was not checked.

DEA response to the shortage: FDA told DEA that it had added methylphenidate HCl extended-release tablets to its drug shortage list on July 26, 2023, and asked for higher quotas; DEA then raised the 2023 aggregate production quota for methylphenidate (for sale) from 41,800 kg to 53,283 kg (order signed Sep 29, 2023; published Oct 3, 2023, 88 FR 68147).

How methylphenidate ER 10/20 mg tablets compare to other methylphenidates

Methylphenidate ER tablets 10/20 mg (Ritalin-SR type) are a different product from Concerta, Relexxii and their 18–72 mg methylphenidate ER tablet generics, which use an osmotic (OROS-type) design with an immediate-release overcoat and are labeled for about 12 hours. They are not interchangeable mg for mg. Effect windows below come from each product’s FDA labeling, not head-to-head comparisons.

Medication Studied effect window / dosing (label) Release design Key practical notes
Methylphenidate ER tablets 10/20 mg (Ritalin-SR type; generic) Duration of action about 8 h (label) Extended-release tablet; slower absorption than IR (time to peak ~4.7 h in children); labeling describes no osmotic system or IR overcoat Generic only (Ritalin-SR brand discontinued). Not interchangeable with Concerta-type 18–72 mg ER tablets. Swallow whole.
Concerta (OROS tablet) Effects maintained through 12 h after dosing Osmotic tablet: drug overcoat + gradual osmotic delivery Swallow whole. AB-rated generics. ER tablets on FDA shortage list (brand reported available).
Relexxii (osmotic tablet) Effects maintained through 12 h after dosing Osmotic ER tablet Seven strengths incl. 45, 63, 72 mg; swallow whole. Listed Available on FDA shortage page.
Ritalin (IR tablet) Short-acting; dosed 2–3 times daily Immediate release Scored 10 and 20 mg tablets; take 30–45 min before meals.
Ritalin LA (bimodal beads) About 8 h in classroom studies; label gives no fixed duration (built to match 2 IR doses 4 h apart) 50% immediate + 50% delayed-release beads Capsule can be sprinkled. Brand status: sources differ; AB1 generics.
Metadate CD (beads) Labeled for ages 6 and older (pediatric only); morning and afternoon teacher ratings 30% immediate + 70% extended-release beads Sprinkle allowed. AB2 generics are not Ritalin LA substitutes.
Methylphenidate chewable tablets (IR; generic) Short-acting; dosed 2–3 times daily Immediate-release chewable tablet Take with at least 8 oz (a full glass) of fluid: choking risk. Some contain aspartame (phenylalanine). Brand Methylin chewable discontinued; AB generics.

Other methylphenidate-family pages: Concerta, Ritalin, Methylin, Ritalin LA, Metadate CD, Aptensio XR, Adhansia XR, Focalin, Focalin XR, Azstarys, Jornay PM, Cotempla XR-ODT, QuilliChew ER, Quillivant XR, Daytrana, Relexxii, Methylphenidate chewable tablets.

Clinical evidence from published studies

These findings come from published research, not from the FDA label. The FDA label is the official source for approved uses, doses and warnings. Results from studies may not apply to you. Uses marked off-label are not FDA-approved. Talk with your prescriber before making any change.

Items summarize peer-reviewed publications, checked against the PubMed abstract (or full text where stated); figures are reproduced only where the source states them. The FDA label governs approved indications and dosing. Off-label items are not FDA-approved uses. Industry funding or sponsor affiliation is noted where the PubMed record shows it; absence of a note does not mean no industry involvement.

Studies of this medicine (1 study)
  • Randomized controlled trial

    Standard and sustained-release methylphenidate, Dexedrine Spansule, pemoline

    In a summer treatment program study of 22 children, four options gave generally similar benefits: standard methylphenidate twice a day, and once-daily morning doses of sustained-release methylphenidate (Ritalin SR-20), Dexedrine Spansule or pemoline. Dexedrine Spansule and pemoline gave the most consistent effects. On a computer attention test, all four started working within 2 hours and lasted about 9 hours.

    Double-blind placebo-controlled crossover, n=22, summer treatment program (recreation + classroom). Generally equivalent benefits; Spansule and pemoline most consistent (recommended for 10 of 15 responders). CPT: effect within 2 h, lasting 9 h, for all four. Small, older study (1990).

    Pelham WE Jr, Greenslade KE, Vodde-Hamilton M, et al. (1990). Relative efficacy of long-acting stimulants on children with attention deficit-hyperactivity disorder: a comparison of standard methylphenidate, sustained-release methylphenidate, sustained-release dextroamphetamine, and pemoline. Pediatrics 86(2):226-37. PubMed 2196522

How ADHD medicines compare (6 studies)
  • Network meta-analysis

    ADHD medicines (class)

    A large analysis of 133 short-term trials found that every ADHD medicine studied worked better than placebo on clinician ratings in children and teens. Amphetamines had the largest average effect, and methylphenidate was the only medicine also shown to beat placebo on teacher ratings. Amphetamines and guanfacine led to more stopping for side effects than placebo in children. Weighing benefit and side effects, the authors favored methylphenidate first in children and amphetamines first in adults. There was too little data to judge effects beyond about 12 weeks.

    Network meta-analysis of 133 double-blind RCTs (efficacy near 12 wk: 10,068 children/adolescents; 8,131 adults). Children, clinician-rated SMD vs placebo: amphetamines −1.02 (95% CI −1.19 to −0.85), methylphenidate −0.78 (−0.93 to −0.62), atomoxetine −0.56 (−0.66 to −0.45). Teacher-rated: only methylphenidate (−0.82, −1.16 to −0.48) and modafinil separated from placebo. Adults, clinician-rated: amphetamines −0.79 (−0.99 to −0.58), methylphenidate −0.49 (−0.64 to −0.35), atomoxetine −0.45 (−0.58 to −0.32). Discontinuation for adverse events vs placebo: amphetamines OR 2.30 (1.36–3.89) in children and 3.26 (1.54–6.92) in adults; guanfacine 2.64 (1.20–5.81) in children; atomoxetine 2.33 (1.28–4.25) and methylphenidate 2.39 (1.40–4.08) in adults only. Head-to-head clinician-rated efficacy favored amphetamines over methylphenidate, atomoxetine and modafinil. Insufficient data at 26 and 52 weeks.

    Funding / affiliation: Non-industry (Stichting Eunethydis; UK NIHR Oxford Health BRC).

    Cortese S, Adamo N, Del Giovane C, et al. (2018). Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry 5(9):727-738. DOI · PubMed 30097390

  • Network meta-analysis

    ADHD treatments in children and teens (class)

    Across 190 trials in children and teens, methylphenidate, amphetamine, atomoxetine, guanfacine and clonidine all worked better than placebo. Methylphenidate and amphetamine appeared more effective than atomoxetine and guanfacine. Behavioral therapy combined with a stimulant appeared better than either medicine type alone. Most effective medicines also caused harms such as reduced appetite, weight loss and sleep problems.

    Bayesian network meta-analyses of 190 RCTs (52 interventions, 26,114 participants; ≥3 weeks follow-up). Medications more efficacious than placebo: methylphenidate, amphetamine, atomoxetine, guanfacine, clonidine. Methylphenidate and amphetamine more efficacious than atomoxetine and guanfacine; methylphenidate and clonidine better accepted (all-cause discontinuation) than placebo and atomoxetine. Behavioural therapy plus stimulants appeared superior to stimulants or nonstimulants alone. Harms included anorexia, weight loss and insomnia. Results expressed as ORs with credible intervals (not reproduced here).

    Catalá-López F, Hutton B, Núñez-Beltrán A, et al. (2017). The pharmacological and non-pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: A systematic review with network meta-analyses of randomised trials. PLoS One 12(7):e0180355. DOI · PubMed 28700715

  • Network meta-analysis

    ADHD medicines (class): dose

    An analysis of how benefit changes with dose (113 trials) found that, in children and teens, extra benefit stopped rising above about 45 mg/day of methylphenidate, 25 mg/day of amphetamines and 4 mg/day of guanfacine, although data at higher doses were thin. Stopping for side effects rose at higher amphetamine doses, and at methylphenidate doses above 50 mg/day in adults. No dose–benefit pattern was found for atomoxetine in fixed-dose studies.

    Dose-effect NMA (Bayesian restricted cubic splines) of 113 double-blind RCTs: 68 pediatric (14,138 participants), 45 adult (11,016). Children/adolescents: median efficacy increased up to ~45 mg/day methylphenidate, ~25 mg/day amphetamines, ~4 mg/day guanfacine, with no evidence of added benefit above (wide credible intervals). Adults: amphetamines plateaued above ~50 mg/day; methylphenidate showed no plateau (sparse data). Dose-dependent AE-related discontinuation: amphetamines above 25 mg/day (children) and 50 mg/day (adults); methylphenidate above 50 mg/day in adults, no clear dose dependence in children. No dose-effect pattern for atomoxetine (fixed-dose studies) or modafinil. Needs full-text check: how amphetamine products were converted to a common dose scale is not stated in the abstract.

    Funding / affiliation: Non-industry (UK NIHR).

    Nourredine M, Jurek L, Hamza T, et al. (2026). Pharmacological interventions for ADHD: a systematic review and dose-effect network meta-analysis. Lancet Psychiatry 13(6):485-495. DOI · PubMed 42134365

  • Meta-analysis

    Amphetamines vs methylphenidate (class)

    A pooled analysis of 23 placebo-controlled trials in children and teens found that amphetamine products had somewhat larger average effects than methylphenidate products, even after adjusting for differences in study design. The trials did not compare the two directly.

    Meta-analysis/meta-regression of 23 double-blind placebo-controlled trials (11 drugs, 19 outcome measures). Effect sizes for amphetamine products were significantly, though moderately, greater than for methylphenidate products after correcting for design features. Indirect comparison (no head-to-head trials).

    Faraone SV, Buitelaar J (2010). Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis. Eur Child Adolesc Psychiatry 19(4):353-64. DOI · PubMed 19763664

  • Network meta-analysis

    Adult ADHD treatments (class)

    In adults (113 trials), stimulants and atomoxetine were the only treatments that reduced core symptoms on both self-ratings and clinician ratings at 12 weeks. Several psychological approaches (such as CBT and mindfulness) helped only on clinician ratings. Atomoxetine and guanfacine were stopped more often than placebo.

    Component NMA, 113 RCTs (14,887 adults). 12-week core symptoms: atomoxetine SMD −0.38 self-rated (−0.56 to −0.21), −0.51 clinician-rated (−0.64 to −0.37); stimulants about −0.39 self-rated (CI −0.52 to −0.26) and −0.61 clinician-rated (−0.71 to −0.51). CBT (−0.76), cognitive remediation, mindfulness, psychoeducation and tDCS beat placebo on clinician-rated measures only. Acceptability worse than placebo: atomoxetine OR 1.43 (1.14–1.80), guanfacine 3.70 (1.22–11.19).

    Ostinelli EG, Schulze M, Zangani C, et al. (2025). Comparative efficacy and acceptability of pharmacological, psychological, and neurostimulatory interventions for ADHD in adults: a systematic review and component network meta-analysis. Lancet Psychiatry 12(1):32-43. DOI · PubMed 39701638

  • Meta-analysis

    Methylphenidate vs atomoxetine (children)

    Combining nine head-to-head trials (2,762 participants), methylphenidate and atomoxetine did not differ overall in effect or response rates. In a subgroup, long-acting OROS methylphenidate (the Concerta-type formulation) worked better than atomoxetine, while immediate-release methylphenidate did not.

    Meta-analysis of 9 RCTs (n=2,762) comparing methylphenidate and atomoxetine. Overall SMD 0.09 (95% CI −0.08 to 0.26), NS; response RR 0.93 (0.76–1.14). Subgroup: OROS methylphenidate SMD 0.32 (0.12–0.53) favoring OROS; immediate-release methylphenidate −0.04 (−0.19 to 0.12). An update (Rezaei 2016, PMID 27390695; 11 studies, 2,772) reported the same pattern (OROS SMD 0.31, 0.16–0.47).

    Hanwella R, Senanayake M, de Silva V (2011). Comparative efficacy and acceptability of methylphenidate and atomoxetine in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis. BMC Psychiatry 11:176. DOI · PubMed 22074258

    See also: Rezaei G, Hosseini SA, Akbari Sari A, et al. (2016). Med J Islam Repub Iran. PubMed 27390695

Long-term real-world outcomes (5 studies)
  • Cohort / registry study

    ADHD medicines (class): risk of death

    In a Swedish national study of 148,578 people aged 6 to 64 newly diagnosed with ADHD, those who started ADHD medicine had a lower risk of dying over the next 2 years (39 vs 48 deaths per 10,000 people). The difference came mainly from fewer deaths from unnatural causes such as injuries, accidental poisonings and suicide; deaths from natural causes did not differ significantly. This is an observational study: it shows an association, not proof that the medicine caused the difference.

    Target trial emulation, Swedish registers (diagnosis 2007–2018; 2-year follow-up); n=148,578, of whom 84,204 (56.7%) started medication within 3 months. 2-year mortality 39.1 vs 48.1 per 10,000 (risk difference −8.9; 95% CI −17.3 to −0.6). All-cause HR 0.79 (0.70–0.88); unnatural-cause HR 0.75 (0.66–0.86); natural-cause HR 0.86 (0.71–1.05), not significant. Class-level estimate (all ADHD medicines); the abstract does not report methylphenidate separately.

    Li L, Zhu N, Zhang L, et al. (2024). ADHD Pharmacotherapy and Mortality in Individuals With ADHD. JAMA 331(10):850-860. DOI · PubMed 38470385

  • Cohort / registry study

    ADHD medicines (class; 88% started on methylphenidate)

    Using the same Swedish registers (148,581 people aged 6 to 64 newly diagnosed with ADHD), starting ADHD medicine was linked over 2 years to fewer first episodes of suicidal behavior (about 17% fewer), substance misuse (15%), transport accidents (12%) and criminal offenses (13%). Accidental injuries were not significantly reduced for first events, but repeat events of all five kinds were lower. Methylphenidate was the first medicine for 88% of people who started treatment. Observational: an association, not proof.

    Target trial emulation, Swedish registers 2007–2020; n=148,581; 84,282 (56.7%) initiated treatment, methylphenidate in 74,515 (88.4%). First events, adjusted IRR: suicidal behaviour 0.83 (95% CI 0.78–0.88); substance misuse 0.85 (0.83–0.87); transport accidents 0.88 (0.82–0.94); criminality 0.87 (0.83–0.90); accidental injuries 0.98 (0.96–1.01), not significant. Recurrent events: all five reduced (IRR 0.75–0.96). Class-level estimates.

    Zhang L, Zhu N, Sjölander A, et al. (2025). ADHD drug treatment and risk of suicidal behaviours, substance misuse, accidental injuries, transport accidents, and criminality: emulation of target trials. BMJ 390:e083658. DOI · PubMed 40803836

  • Self-controlled case series

    ADHD medicines (class): changes over time

    A Swedish study of 247,420 people who used ADHD medicine between 2006 and 2020 compared periods on and off medicine in the same people. Medicine periods were consistently linked to fewer self-harm events, unintentional injuries, traffic crashes and crimes. However, the links for injuries, crashes and crime became weaker over time as the share of people taking ADHD medicine rose from 0.6% to 2.8%.

    Self-controlled case series, Swedish registers, ages 4–64, n=247,420; periods 2006–2010, 2011–2015 and 2016–2020 (medication prevalence 0.6% to 2.8%). Medicated vs non-medicated IRR ranges: self-harm 0.77 (0.73–0.81) to 0.85 (0.82–0.88); unintentional injury 0.87 (0.84–0.89) to 0.93 (0.91–0.95); traffic crashes 0.71 (0.67–0.77) to 0.87 (0.83–0.91); crime 0.73 (0.71–0.75) to 0.84 (0.82–0.85). Weakening over time for injury, crashes and crime (P for trend <.01), not fully explained by changes in age and sex mix.

    Li L, Coghill D, Sjölander A, et al. (2025). Increased Prescribing of Attention-Deficit/Hyperactivity Disorder Medication and Real-World Outcomes Over Time. JAMA Psychiatry 82(8):830-837. DOI · PubMed 40560574

  • Cohort / registry study

    ADHD medicines (class): criminal convictions

    Comparing the same 25,656 people with ADHD in Sweden during periods on and off medicine (2006–2009), criminal convictions were 32% lower in men and 41% lower in women while they were taking ADHD medicine. This links treatment with fewer crimes but cannot prove the medicine caused the drop.

    Swedish registers 2006–2009, n=25,656; stratified (within-individual) Cox regression, medicated vs non-medicated periods. Criminality: men adjusted HR 0.68 (95% CI 0.63–0.73); women HR 0.59 (0.50–0.70). Reductions of 17% to 46% in male sensitivity analyses (including by drug type, stimulant vs nonstimulant, and type of crime). Class-level estimate.

    Funding / affiliation: Non-industry (Swedish Research Council and others).

    Lichtenstein P, Halldner L, Zetterqvist J, et al. (2012). Medication for attention deficit-hyperactivity disorder and criminality. N Engl J Med 367(21):2006-14. DOI · PubMed 23171097

  • Cohort / registry study

    ADHD medicines (class): serious transport accidents

    Following 17,408 people with ADHD in Sweden from 2006 to 2009, men had 58% fewer serious transport accidents (emergency visits or deaths) during periods when they were taking ADHD medicine than when they were not. No significant difference was found in women.

    Swedish registers 2006–2009, n=17,408. ADHD vs no ADHD, serious transport accidents: men adjusted HR 1.47 (95% CI 1.32–1.63), women 1.45 (1.24–1.71). Within-individual comparison of medicated vs non-medicated periods: men HR 0.42 (0.23–0.75); women not statistically significant. The authors estimated that 41% to 49% of accidents in men with ADHD might have been avoided with treatment throughout follow-up (a modelled estimate). Class-level estimate.

    Chang Z, Lichtenstein P, D'Onofrio BM, et al. (2014). Serious transport accidents in adults with attention-deficit/hyperactivity disorder and the effect of medication: a population-based study. JAMA Psychiatry 71(3):319-25. DOI · PubMed 24477798

Heart and blood pressure (10 studies)
  • Meta-analysis

    Methylphenidate, amphetamines, atomoxetine (children)

    Pooling 18 trials in 5,837 children and teens, methylphenidate, amphetamines and atomoxetine all raised systolic blood pressure slightly on average. Amphetamines and atomoxetine also raised heart rate and diastolic pressure; methylphenidate did not. About 2% stopped because of heart-related effects. The authors advise regular heart rate and blood pressure checks.

    Systematic review/meta-analysis, 18 trials (10 MPH, 5 AMP, 7 ATX), n=5,837, mean 28.7 weeks. Pre–post SBP SMD: MPH 0.25 (0.08–0.42), AMP 0.09 (0.03–0.15), ATX 0.16 (0.04–0.27). DBP: AMP 0.16 (0.03–0.29), ATX 0.22 (0.10–0.34); HR: AMP 0.37 (0.13–0.60), ATX 0.43 (0.26–0.60); MPH no pre–post effect on DBP or HR. No significant head-to-head differences. 2% discontinued for any cardiovascular effect.

    Hennissen L, Bakker MJ, Banaschewski T, et al. (2017). Cardiovascular Effects of Stimulant and Non-Stimulant Medication for Children and Adolescents with ADHD: A Systematic Review and Meta-Analysis of Trials of Methylphenidate, Amphetamines and Atomoxetine. CNS Drugs 31(3):199-215. DOI · PubMed 28236285

  • Network meta-analysis

    ADHD medicines (class)

    Pooling 102 short-term trials, most ADHD medicines raised blood pressure and pulse modestly, and stimulants did not raise them more than atomoxetine or viloxazine. Guanfacine lowered blood pressure and pulse. The authors advise monitoring blood pressure and pulse with any ADHD medicine, not just stimulants.

    NMA of 102 RCTs (13,315 children/adolescents; 9,387 adults; median 7 weeks). Children, mean increase vs placebo: SBP 1.07 (atomoxetine) to 1.81 mm Hg (methylphenidate); DBP 1.93 (amphetamines) to 2.42 (methylphenidate); pulse 2.79 bpm (viloxazine) to 5.58 bpm (atomoxetine). Amphetamines, lisdexamfetamine and methylphenidate not associated with larger increments than atomoxetine or viloxazine. Guanfacine in children: SBP −2.83 (−3.8 to −1.85), DBP −2.08, pulse −4.06. Only four RCTs informed medium-term effects. CINeMA confidence mostly low to moderate in children, very low in adults.

    Funding / affiliation: Non-industry (UK NIHR).

    Farhat LC, Lannes A, Del Giovane C, et al. (2025). Comparative cardiovascular safety of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry 12(5):355-365. DOI · PubMed 40203844

  • Meta-analysis

    Methylphenidate and atomoxetine

    Pooling 22 studies (46,107 people), methylphenidate raised heart rate and systolic blood pressure compared with placebo in young people and adults; in children, atomoxetine raised them more than methylphenidate. Serious cardiac events did not differ.

    Meta-analysis/meta-regression of 22 studies (n=46,107). MPH vs placebo: greater pre–post HR (p<0.001) and SBP (p<0.001) increases in youth and adults. Children/adolescents: ATX > MPH for HR (p=0.025) and SBP (p<0.001). Moderators: age, dose, duration. No difference in adverse cardiac events (MPH vs placebo or ATX). Effects reported as standardized differences, not bpm/mm Hg, in the abstract.

    Liang EF, Lim SZ, Tam WW, et al. (2018). The Effect of Methylphenidate and Atomoxetine on Heart Rate and Systolic Blood Pressure in Young People and Adults with Attention-Deficit Hyperactivity Disorder (ADHD): Systematic Review, Meta-Analysis, and Meta-Regression. Int J Environ Res Public Health 15(8). DOI · PubMed 30127314

  • Case-control study

    ADHD medicines (class), long-term use

    In a Swedish registry study of 278,027 people with ADHD (ages 6–64), longer total use of ADHD medicine was linked to a higher risk of cardiovascular disease, about 4% more per year of use, mainly high blood pressure and arterial disease. This kind of study shows an association, not proof of cause.

    Nested case-control (Swedish registers, 2007–2020): 10,388 CVD cases vs 51,672 matched controls. Cumulative use vs non-use: 3–≤5 y AOR 1.27 (1.17–1.39); >5 y 1.23 (1.12–1.36). Per year of use AOR 1.04 (1.03–1.05), steeper in first 3 years (1.08). Hypertension 3–≤5 y AOR 1.72 (1.51–1.97), >5 y 1.80 (1.55–2.08). Similar in under-25s and adults. Not broken down by individual drug in the abstract.

    Zhang L, Li L, Andell P, et al. (2024). Attention-Deficit/Hyperactivity Disorder Medications and Long-Term Risk of Cardiovascular Diseases. JAMA Psychiatry 81(2):178-187. DOI · PubMed 37991787

  • Self-controlled case series

    Methylphenidate (all forms)

    A South Korean study of 1,224 children and teens who had a heart-related event while on methylphenidate found a higher rate of heart rhythm problems during treatment periods, and a higher rate of heart attack in the first weeks after starting. Absolute risk is likely low. No increase was seen for high blood pressure, stroke or heart failure.

    Nationwide self-controlled case series (2008–2011), 1,224 patients ≤17 y with an incident CV event and methylphenidate exposure. Arrhythmia IRR 1.61 (95% CI 1.48–1.74) across exposed periods, highest with congenital heart disease. Myocardial infarction 1.33 (0.90–1.98) overall, elevated in the early 8–56 day window. No significant increase for hypertension, ischaemic stroke or heart failure.

    Shin JY, Roughead EE, Park BJ, et al. (2016). Cardiovascular safety of methylphenidate among children and young people with attention-deficit/hyperactivity disorder (ADHD): nationwide self controlled case series study. BMJ 353:i2550. DOI · PubMed 27245699

  • Cohort / registry study

    Methylphenidate (all forms)

    In a large Taiwanese cohort of 224,732 people with ADHD, methylphenidate users did not have a higher risk of major cardiovascular events than non-users over the study period.

    Propensity-matched cohort: 224,732 patients. Major CV events, MPH >7 days vs non-users HR 0.85 (0.72–0.99); >180 days 0.83 (0.69–1.00). Authors call for more evidence on long-term use.

    Liao HC, Hsu CN, Lin FJ, et al. (2024). Association between methylphenidate use and long-term cardiovascular risk in paediatric patients with attention deficit and hyperactivity disorder. BMJ Paediatr Open 8(1). DOI · PubMed 39231572

  • Case-control study

    Methylphenidate (all forms)

    A Danish general-population study (median age 72 among cardiac arrest cases) found methylphenidate use was linked to higher odds of out-of-hospital cardiac arrest, especially in the first 6 months after starting. Few users were in the study, and most were much older than typical ADHD patients.

    Nested case-control: 46,578 OHCA cases (median 72 y) vs 232,890 matched controls; MPH used by 80 cases, 166 controls. OR 1.78 (1.32–2.40); recent starters ≤180 days 2.59 (1.28–5.23). Persisted in those without hospital-diagnosed ADHD.

    Eroglu TE, Halili A, Arulmurugananthavadivel A, et al. (2023). Use of methylphenidate is associated with increased risk of out-of-hospital cardiac arrest in the general population: a nationwide nested case-control study. Eur Heart J Cardiovasc Pharmacother 9(7):658-665. DOI · PubMed 37070942

  • Clinical practice guideline

    Stimulants and nonstimulants (children and teens)

    The 2019 American Academy of Pediatrics guideline says stimulants have not been shown to raise the risk of sudden death. Before starting, clinicians should ask about heart symptoms and a family history of sudden death or inherited heart rhythm or muscle conditions, and arrange further evaluation if any risk factor is present. It describes an ECG as part of that extra evaluation for nonstimulants when risk factors are present.

    AAP clinical practice guideline (Wolraich 2019), full text: obtain history of specific cardiac symptoms and family history of sudden death, cardiovascular symptoms, WPW, HCM and long QT before stimulants; if risk factors are present, obtain additional evaluation. For nonstimulants with risk factors, the additional evaluation is described as an ECG, with pediatric cardiology referral if abnormal. No routine ECG is recommended for patients without risk factors.

    Wolraich ML, Hagan JF Jr, Allan C, et al. (2019). Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. Pediatrics 144(4). DOI · PubMed 31570648

  • Clinical practice guideline

    ADHD medicines (class)

    The European ADHD Guidelines Group found no evidence that a routine ECG before starting ADHD medicine adds benefit. It notes that the American Heart Association first suggested an ECG as standard in 2008 and then left it to the clinician’s judgment. A 2009 Canadian joint statement likewise recommends a careful history and examination, with an ECG or cardiology referral only when these suggest a problem.

    European Guidelines Group (EUNETHYDIS) review of adverse effects, full text: “no current evidence to suggest an incremental benefit for routine ECG assessment” before medication; AHA in 2008 initially recommended ECG as standard, then changed this to clinician discretion; ECG screening not considered cost-effective for preventing sudden death in the general pediatric population. Canadian Paediatric Society / Canadian Cardiovascular Society / CACAP joint statement (Warren 2009, abstract): thorough history and physical examination; no routine ECG screening or cardiac subspecialist consultation unless indicated by history or examination.

    Graham J, Banaschewski T, Buitelaar J, et al. (2011). European guidelines on managing adverse effects of medication for ADHD. Eur Child Adolesc Psychiatry 20(1):17-37. DOI · PubMed 21042924

    See also: Warren AE, Hamilton RM, Bélanger SA, et al. (2009). Can J Cardiol. DOI · PubMed 19898693

  • Cohort / registry study

    Children with ADHD (screening ECG)

    At one U.S. center, 1,470 children with ADHD had a screening ECG. About 8% were read as abnormal, but heart disease was found in only 5 children (0.3%), so most abnormal results were false alarms. Finding each true case cost about $17,000 in testing.

    Retrospective review of screening ECGs in 1,470 patients <21 y with ADHD (Apr–Sep 2008): 119 abnormal (8.1%); follow-up included 63 echocardiograms, 5 stress tests, 9 Holters; cardiac disease in 5 (0.3%: ventricular pre-excitation 2, bicuspid aortic valve 2, secundum ASD 1); positive predictive value 4.2%; mean cost $58 per child and $17,162 per true positive. The authors note screening can find asymptomatic disease but with low PPV.

    Mahle WT, Hebson C, Strieper MJ (2009). Electrocardiographic screening in children with attention-deficit hyperactivity disorder. Am J Cardiol 104(9):1296-9. DOI · PubMed 19840580

Growth (6 studies)
  • Cohort / registry study

    Methylphenidate (all forms)

    In a German national health survey of 4,244 boys, methylphenidate use was linked to very low body-mass index in some age groups, but not to short stature or blood pressure changes. Numbers of treated boys were small.

    KiGGS survey analysis: 4,244 boys (MPH <12 months n=65; ≥12 months n=53; ADHD controls 320; non-ADHD 3,806). BMI ≤3rd percentile more likely in pre-pubertal boys with <12 months of MPH and pubertal/post-pubertal boys with ≥12 months. No association with low height (≤3rd percentile) or BP changes.

    McCarthy S, Neubert A, Man KKC, et al. (2018). Effects of long-term methylphenidate use on growth and blood pressure: results of the German Health Interview and Examination Survey for Children and Adolescents (KiGGS). BMC Psychiatry 18(1):327. DOI · PubMed 30305167

  • Randomized controlled trial

    Stimulants (mostly OROS methylphenidate), children 5–12

    Children whose weight dropped after starting a stimulant were randomly assigned to medicine on school days only (a planned break on weekends and holidays), a daily high-calorie snack, or monthly checks. All three helped weight gain, but none of them sped up growth in height. Most families in the school-days-only group went back to giving the medicine after school because symptoms got worse.

    RCT, 230 children aged 5–12 starting stimulants (78%, mainly OROS-MPH) or behavioral treatment for 30 months; children with a BMI decline >0.5 z after 6 months (n=71) were randomized to monthly monitoring, drug holidays (medication limited to school days) or a 150-kcal daily supplement. Weight velocity rose after randomization across all arms (β=0.271, SE 0.027, p<.001); per actual use, supplementation (p<.01) and holidays (p<.05) increased weight velocity more than monitoring. No arm increased height velocity. Full text: parents gave medication on only 5% of weekend days in the holiday arm; 16 of 23 (70%) reverted to after-school dosing because of worsening symptoms.

    Waxmonsky JG, Pelham WE 3rd, Campa A, et al. (2020). A Randomized Controlled Trial of Interventions for Growth Suppression in Children With Attention-Deficit/Hyperactivity Disorder Treated With Central Nervous System Stimulants. J Am Acad Child Adolesc Psychiatry 59(12):1330-1341. DOI · PubMed 31473291

  • Randomized controlled trial

    Methylphenidate (immediate-release, twice daily)

    In a 4-week trial in boys taking methylphenidate twice a day, swapping in a placebo on weekends led to less trouble sleeping and a trend toward better appetite. ADHD symptoms on weekends (parent ratings) and on the following Monday (teacher ratings) did not rise significantly. The study was small and short.

    Double-blind RCT, 28 days, boys with ADHD: MPH b.i.d. 7 days/week (n=21) vs weekdays with weekend placebo (n=19). No significant group difference in parent weekend ratings (endpoint p=0.41, ES 0.26) or Monday teacher ratings (p=0.99, ES 0.002). Weekend placebo: less insomnia (F=3.96, p=0.05) and a trend to less appetite interference (F=3.18, p=0.08). Growth was not an outcome.

    Martins S, Tramontina S, Polanczyk G, et al. (2004). Weekend holidays during methylphenidate use in ADHD children: a randomized clinical trial. J Child Adolesc Psychopharmacol 14(2):195-206. DOI · PubMed 15319017

  • Randomized controlled trial

    Methylphenidate (long-term use)

    Children on long-term methylphenidate were randomly assigned to stop or continue it over two summers. One summer off was followed by more weight gain but no height difference; two summers off had a significant positive effect on height. The study could not show whether this changes final adult height.

    Controlled withdrawal study: hyperactive children on long-term MPH randomized to be off or remain on medication over two consecutive summers. After one summer: no height difference, higher weight in the off-medication group. After two summers: significant positive effect on height (not weight). Authors note the results do not address long-term effects on height. Needs full-text check: sample size and effect sizes are not in the abstract.

    Klein RG, Landa B, Mattes JA, et al. (1988). Methylphenidate and growth in hyperactive children. A controlled withdrawal study. Arch Gen Psychiatry 45(12):1127-30. DOI · PubMed 3058088

  • Systematic review (narrative)

    ADHD medicines (mostly stimulants), children and teens

    A review of 22 studies from 1972 to 2013 found that 25–70% of families take breaks from ADHD medicine, most often during school holidays. Breaks are used to check whether medicine is still needed and to manage side effects. Longer breaks were linked to better growth, and shorter breaks could reduce sleep problems and improve appetite.

    Literature review (22 studies, 1972–2013) of drug holidays in children and adolescents. Prevalence 25–70% of families, more often in school holidays; purposes: testing ongoing need, managing adverse effects and tolerance. Positive impact on growth with longer breaks; shorter breaks could reduce insomnia and improve appetite. Study quality not graded in the abstract.

    Ibrahim K, Donyai P (2015). Drug Holidays From ADHD Medication: International Experience Over the Past Four Decades. J Atten Disord 19(7):551-68. DOI · PubMed 25253684

  • Cohort / registry study

    Stimulants (MTA follow-up into adulthood)

    In the long-term follow-up of the MTA study, young adults who had taken stimulants consistently through childhood were on average about 2.4 cm shorter than those who took them inconsistently, and treated groups were about 2.6 cm shorter than those who took little or none. Consistent long-term use was not linked to fewer adult ADHD symptoms. These groups were not randomized.

    Observational follow-up of the MTA (579 randomized; 515 followed; 289 classmates as local norms), outcomes at ~25 years. Adult height: Consistent/Inconsistent users 2.55 ± 0.73 cm shorter than Negligible users (p<.0005); Consistent 2.36 ± 1.13 cm shorter than Inconsistent (p<.04). Naturalistic-subgroup comparisons for symptom severity were not significant. Full text: height was measured in 402 ADHD participants (Consistent subgroup n=33).

    Swanson JM, Arnold LE, Molina BSG, et al. (2017). Young adult outcomes in the follow-up of the multimodal treatment study of attention-deficit/hyperactivity disorder: symptom persistence, source discrepancy, and height suppression. J Child Psychol Psychiatry 58(6):663-678. DOI · PubMed 28295312

Psychosis and mania (6 studies)
  • Cohort / registry study

    Amphetamine vs methylphenidate

    In US insurance data on 221,846 adolescents and young adults (13–25) starting a stimulant, new psychosis treated with an antipsychotic occurred in about 1 in 660. It was about twice as common with amphetamine (0.21%) as with methylphenidate (0.10%).

    Propensity-matched cohort (2 claims databases, 2004–2015): 110,923 MPH vs 110,923 amphetamine starters. 343 psychosis episodes: 106 (0.10%) MPH vs 237 (0.21%) amphetamine; HR 1.65 (95% CI 1.31–2.09) for amphetamine.

    Funding / affiliation: Non-industry (NIMH and others).

    Moran LV, Ongur D, Hsu J, et al. (2019). Psychosis with Methylphenidate or Amphetamine in Patients with ADHD. N Engl J Med 380(12):1128-1138. DOI · PubMed 30893533

  • Case-control study

    Amphetamines (class)

    Among young people hospitalized for psychiatric reasons, recent prescription amphetamine use was linked to higher odds of a first episode of psychosis or mania, and the link was strongest at higher doses (above 30 mg of dextroamphetamine-equivalent). Recent methylphenidate use was not linked. Because only hospitalized patients were compared, results may not apply to everyone.

    Case-control (McLean Hospital EHR, 2005–2019): 1,374 cases (incident psychosis/mania, ages 16–35) vs 2,748 psychiatric controls. Past-month amphetamine aOR 2.68 (1.90–3.77); >30 mg dextroamphetamine equivalents ~5.28-fold. Methylphenidate aOR 0.91 (0.54–1.55). Selection bias acknowledged.

    Moran LV, Skinner JP, Shinn AK, et al. (2024). Risk of Incident Psychosis and Mania With Prescription Amphetamines. Am J Psychiatry 181(10):901-909. DOI · PubMed 39262211

  • Meta-analysis

    Methylphenidate (all forms)

    A Cochrane-method review could not confirm or rule out that methylphenidate causes psychotic symptoms such as hallucinations in children. Such symptoms were reported in roughly 1 to 2.5 of every 100 children in the available studies, and families should know to report them.

    Systematic review: 10 RCTs (1,103 participants), 17 non-randomised studies, 12 case reports/series. RCTs: 10/654 MPH vs 1/508 placebo, RR 2.07 (0.58–7.35), underpowered, 9/10 high risk of bias. Non-randomised pooled prevalence 1.2% (0.7–2.4). One comparative cohort RR 1.36 (1.17–1.57), critical risk of bias. Possible frequency 1.1–2.5%.

    Ramstad E, Storebø OJ, Gerner T, et al. (2018). Hallucinations and other psychotic symptoms in response to methylphenidate in children and adolescents with attention-deficit/hyperactivity disorder: a Cochrane systematic review with meta-analysis and trial sequential analysis(). Scand J Child Adolesc Psychiatr Psychol 6(1):52-71. DOI · PubMed 33520751

  • Meta-analysis

    Stimulants in ADHD (class): psychosis and bipolar disorder

    Pooling 16 studies of about 391,000 people with ADHD, a 2025 review estimated that roughly 2% to 4% of people treated with stimulants later had psychotic symptoms, a psychotic disorder or bipolar disorder, although results varied widely between studies. Psychosis was more common with amphetamines than with methylphenidate. These studies cannot show that the medicine caused the problems, and the authors advise discussing these risks and watching for them during treatment.

    Systematic review and meta-analysis (searches to Oct 1, 2024), 16 studies, N=391,043 (mean age 12.6 y). Pooled occurrence among stimulant-treated individuals: psychotic symptoms 2.76% (95% CI 0.73–9.88; k=10), psychotic disorder 2.29% (1.52–3.40; k=4), bipolar disorder 3.72% (0.77–16.05; k=4); heterogeneity I² >95%. Psychosis, amphetamines vs methylphenidate: OR 1.57 (1.15–2.16; k=3, n=231,325). Higher occurrence in North American studies, with longer follow-up, more female participants, smaller samples and higher stimulant doses. Observational data; causality not established.

    Salazar de Pablo G, Aymerich C, Chart-Pascual JP, et al. (2025). Occurrence of Psychosis and Bipolar Disorder in Individuals With Attention-Deficit/Hyperactivity Disorder Treated With Stimulants: A Systematic Review and Meta-Analysis. JAMA Psychiatry 82(11):1103-1112. DOI · PubMed 40900605

  • Cohort / registry study

    Methylphenidate in adults with bipolar disorder

    In Swedish national registers, 2,307 adults with bipolar disorder started methylphenidate. Those taking it without a mood stabilizer had a much higher rate of mania in the next 3 months, while those also taking a mood stabilizer did not; their rate was lower than before. The authors advise checking carefully for bipolar disorder before starting a stimulant on its own.

    Linked Swedish registers, 2006–2014; n=2,307 adults with bipolar disorder starting methylphenidate. Within-individual Cox regression comparing mania (hospitalization or new mood-stabilizer dispensing) 0–3 months after start with untreated periods. Methylphenidate monotherapy: HR 6.7 (95% CI 2.0–22.4), similar for months 3–6. With a mood stabilizer: HR 0.6 (0.4–0.9). Similar results counting only hospitalizations for mania.

    Viktorin A, Rydén E, Thase ME, et al. (2017). The Risk of Treatment-Emergent Mania With Methylphenidate in Bipolar Disorder. Am J Psychiatry 174(4):341-348. DOI · PubMed 27690517

  • Cohort / registry study

    Methylphenidate in adults with bipolar disorder (French replication)

    A French national claims study tried to repeat the Swedish findings. In 3,526 adults with bipolar disorder who were taking a mood stabilizer, methylphenidate was not linked to more mania, except at doses above 30 mg. In 2,745 people not taking a mood stabilizer, mania was more common in the 3 months after starting, but that link disappeared in a stricter analysis, and the authors think it may reflect the natural course of the illness.

    French national claims database (SNDS), 2008–2024; self-controlled survival analysis of manic relapse in the 6 months before vs after a new methylphenidate dispensation. No mood stabilizer (n=2,745): inpatient mania diagnoses significantly higher within 3 months, not significant in self-controlled case-crossover analyses. Continuous mood stabilizer (n=3,526): no significant change except at >30 mg methylphenidate. Using new antimanic therapy as the outcome gave outlier results. Effect sizes are not given in the abstract.

    Vidal N, Frileux S, Younes N, et al. (2026). Methylphenidate and manic relapse in bipolar disorders: A replication study in a nationwide claims database. J Psychopharmacol 2698811261443684. DOI · PubMed 42132544

ADHD with other conditions (1 study)
  • Meta-analysis

    ADHD with tic disorders

    In children with ADHD and tics (9 trials), methylphenidate, alpha-2 agonists (clonidine, guanfacine) and atomoxetine improved ADHD symptoms. Alpha-2 agonists and atomoxetine also reduced tics, and methylphenidate did not worsen tics in the short term. Very high doses of dextroamphetamine were linked to worse tics.

    Meta-analysis, 9 studies, 477 subjects. ADHD efficacy: MPH, α2 agonists, desipramine, ATX. Tic improvement: α2 agonists and ATX. No evidence MPH worsened tics short-term; supratherapeutic dextroamphetamine worsened tics. Authors: MPH gave the greatest and most immediate ADHD improvement.

    Bloch MH, Panza KE, Landeros-Weisenberger A, et al. (2009). Meta-analysis: treatment of attention-deficit/hyperactivity disorder in children with comorbid tic disorders. J Am Acad Child Adolesc Psychiatry 48(9):884-893. DOI · PubMed 19625978

Pregnancy (5 studies)

These research findings do not replace the FDA label. For what the label says, see Pregnancy and breastfeeding above.

  • Cohort / registry study

    Methylphenidate and amphetamines

    In very large US and Nordic pregnancy registries, first-trimester methylphenidate was linked to a small increase in heart defects (about 28% higher relative risk), while amphetamines were not linked to more birth defects. Absolute risks remained low.

    Cohort: 1,813,894 US Medicaid pregnancies; Nordic replication 2,560,069. US adjusted RR, MPH: any malformation 1.11 (0.91–1.35), cardiac 1.28 (0.94–1.74); amphetamines: any 1.05 (0.93–1.19), cardiac 0.96 (0.78–1.19). Pooled US+Nordic MPH cardiac RR 1.28 (1.00–1.64). US cardiac risk per 1,000: 12.7 unexposed, 18.8 MPH, 15.4 amphetamines.

    Huybrechts KF, Bröms G, Christensen LB, et al. (2018). Association Between Methylphenidate and Amphetamine Use in Pregnancy and Risk of Congenital Malformations: A Cohort Study From the International Pregnancy Safety Study Consortium. JAMA Psychiatry 75(2):167-175. DOI · PubMed 29238795

  • Meta-analysis

    Stimulants and atomoxetine in pregnancy

    A 2026 review of 25 studies found that, after accounting for differences between mothers, using stimulants or atomoxetine in pregnancy was not linked to more major birth defects or to most pregnancy and child-development problems. A small link with methylphenidate and heart defects, and with a low newborn Apgar score, could not be ruled out and needs more study.

    Systematic review/meta-analysis (25 studies; 23 pooled). Major malformations: unadjusted RR 1.25 (1.14–1.37), adjusted 1.04 (0.97–1.12). Cardiovascular malformations aRR 1.20 (0.88–1.63); methylphenidate-specific aRR 1.33 (1.01–1.74). No adjusted association with miscarriage, preterm birth, low birth weight, SGA, NICU admission or offspring neurodevelopmental disorders. Low 5-min Apgar aRR 1.21 (1.03–1.42). Authors attribute crude associations largely to confounding.

    Komargodski R, Tillawe A, Berlin M, et al. (2026). Pregnancy and Offspring Outcomes After Prenatal Stimulant or Atomoxetine Exposure: A Systematic Review and Meta-analysis. Am J Obstet Gynecol MFM 102165. DOI · PubMed 42887725

  • Cohort / registry study

    Methylphenidate (all forms)

    A Danish registry study of 364,012 pregnancies found methylphenidate in early pregnancy was not linked to more birth defects overall, but there was a possible increase in heart defects (mostly holes between heart chambers).

    Registry cohort (2007–2014) using prenatal and postnatal diagnoses. MPH adjusted PR: malformations overall 1.04 (0.70–1.55); any cardiac 1.65 (0.89–3.05; NNH 92); ventricular septal defect 2.74 (1.03–7.28); severe cardiac 2.59 (0.98–6.90).

    Kolding L, Ehrenstein V, Pedersen L, et al. (2021). Associations Between ADHD Medication Use in Pregnancy and Severe Malformations Based on Prenatal and Postnatal Diagnoses: A Danish Registry-Based Study. J Clin Psychiatry 82(1). DOI · PubMed 33406323

  • Meta-analysis

    Methylphenidate and atomoxetine in pregnancy

    Pooling 10 observational studies, birth defects and miscarriage were not more common in babies of mothers who took methylphenidate or atomoxetine in pregnancy than in unexposed babies.

    Meta-analysis of 10 observational studies. vs unexposed offspring of mothers with ADHD: congenital anomalies OR 1.14 (0.83–1.55), miscarriage 1.01 (0.70–1.47); vs general population: anomalies 1.19 (0.93–1.53; I² 74%), miscarriage 1.05 (0.81–1.37). Preterm birth and birth weight not reported as outcomes in the abstract.

    di Giacomo E, Confalonieri V, Tofani F, et al. (2024). Methylphenidate and Atomoxetine in Pregnancy and Possible Adverse Fetal Outcomes: A Systematic Review and Meta-Analysis. JAMA Netw Open 7(11):e2443648. DOI · PubMed 39504019

  • Meta-analysis

    ADHD medicines in pregnancy (class)

    Pooling 8 cohort studies, ADHD medicine during pregnancy was linked to more newborn intensive-care admissions but not to other maternal or newborn problems; methylphenidate showed a borderline link with heart defects.

    Meta-analysis of 8 cohorts. NICU admission RR 1.88 (1.7–2.08) vs never exposed; 1.38 (1.23–1.54) vs exposure before/after pregnancy only. MPH and cardiac malformation RR 1.27 (0.99–1.63; p=0.065). No association with other outcomes; limited confounder adjustment.

    Jiang HY, Zhang X, Jiang CM, et al. (2019). Maternal and neonatal outcomes after exposure to ADHD medication during pregnancy: A systematic review and meta-analysis. Pharmacoepidemiol Drug Saf 28(3):288-295. DOI · PubMed 30585374

Frequently asked questions

How long does a methylphenidate ER 10 or 20 mg tablet last?

The label says the duration of action is about 8 hours.

Is this the same as Concerta?

No. Concerta and its 18–72 mg generics use an osmotic tablet design meant to last about 12 hours. The 10 and 20 mg ER tablets are an older, different design lasting about 8 hours. They are not interchangeable mg for mg.

Can I crush, split or chew the tablet?

No. The label says to swallow the tablets whole and never crush or chew them.

Is there a brand name?

The original brand, Ritalin-SR, is discontinued. The Orange Book lists SpecGx’s version under the name “Methylin ER”; otherwise these are sold as generic methylphenidate ER tablets.

Can it replace twice-daily Ritalin?

The label says the ER tablet may be used in place of immediate-release tablets when the 8-hour ER dose matches the titrated 8-hour IR dose (for example, 10 mg IR twice daily and 20 mg ER once daily). Your clinician decides whether this fits.

When does it start working?

The label does not say. Blood levels rise more slowly than with regular tablets (peak about 4.7 hours in children vs about 2 hours).

Does food matter?

In the label study, a high-fat meal increased the amount absorbed by about 25% and made the peak come slightly sooner. Take it the same way each day.

Is it in shortage?

ASHP lists some suppliers on back order (Mallinckrodt) and others available (KVK-Tech) as of October 2026. Ask your pharmacy which AB-rated product is in stock.

Is it a controlled substance?

Yes. Like all methylphenidate products it is Schedule II, with a boxed warning about abuse, misuse and addiction. Store it securely.

Do methylphenidate ER tablets cause a crash or rebound as they wear off?

The methylphenidate ER tablet label does not describe a “crash” or rebound effect. The label states a duration of action of about 8 hours (label section 2.2). Nervousness is one of the common side effects listed in the Medication Guide.If ADHD symptoms, irritability or tiredness come back as a dose wears off, tell your prescriber; the timing or dose may need adjusting.

What should I do if I miss a dose of methylphenidate ER tablets?

The methylphenidate ER tablet label does not give instructions for a missed dose. Trouble sleeping is one of its common side effects (Medication Guide). The label only says to take it exactly as prescribed (Medication Guide), so do not take extra to make up for a missed dose; ask your prescriber or pharmacist what to do.

What are the most common side effects of methylphenidate ER tablets?

The Medication Guide lists fast heartbeat, palpitations, headache, trouble sleeping, nervousness, heavy sweating, decreased appetite, dry mouth, nausea and stomach pain. These are not all the possible side effects; call your prescriber for advice about side effects that bother you.

Is an ECG (heart tracing) needed before starting?

Usually not. Before prescribing, the clinician should ask about fainting, chest pain, a racing heartbeat, known heart problems, and any family history of sudden death or heart rhythm problems, and do a physical exam. An ECG or a visit to a heart specialist is used when any of these raise concern. UK, Canadian and European guidance does not call for a routine ECG when there are no such warning signs.

Can my child take breaks from the medicine on weekends or over the summer?

Sometimes, but plan it with the prescriber. Breaks can help with appetite, weight gain and sleep, and the label says children who are not growing or gaining weight as expected may need treatment paused. Breaks have not been shown to reliably make children taller, and ADHD symptoms can come back on days off, so it depends on how much your child struggles without the medicine. A break can also show whether the medicine is still needed.

Can I take Methylphenidate ER tablets while pregnant or breastfeeding?

Tell your clinician if you are pregnant or planning a pregnancy. Studies of methylphenidate in pregnancy have not shown a higher risk of major birth defects or miscarriage. The methylphenidate ER tablets label says small amounts of methylphenidate pass into breast milk; if you breastfeed, decide together with your clinician and watch the baby for agitation, poor sleep, poor feeding, or slow weight gain. A pregnancy registry for ADHD medicines can be reached at 1-866-961-2388.

Prescribing guidelines

Methylphenidate formulations are first-line pharmacologic options for school-age children and adolescents per major guidelines when medication is indicated; the choice of formulation depends on the coverage needed, swallowing ability, cost and availability.

Sources

  • SpecGx LLC. Methylphenidate hydrochloride extended-release tablets, CII (10 mg, 20 mg). Prescribing Information, revised 10/2025. DailyMed (accessed Oct 2026).
  • Novartis Pharmaceuticals Corporation. Ritalin LA (methylphenidate hydrochloride) extended-release capsules, CII. Prescribing Information, revised 09/2025 (Ritalin tablet half-life, Section 12.3). DailyMed (accessed Oct 2026).
  • Granules Pharmaceuticals Inc. Methylphenidate hydrochloride extended-release tablets USP, CII. Prescribing Information, revised 08/2026. DailyMed (accessed Oct 2026).
  • KVK-Tech, Inc. Methylphenidate hydrochloride extended-release tablets USP, CII (ANDA 207488). SPL effective 10/2025. DailyMed (accessed Oct 2026).
  • Ascend Laboratories, LLC (manufactured by Alkem). Methylphenidate hydrochloride extended-release tablets 20 mg (ANDA 212288). SPL effective 09/2022. DailyMed (accessed Oct 2026).
  • U.S. Food and Drug Administration. Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book), data files dated October 2026. FDA.
  • U.S. Food and Drug Administration. Drug Shortages: Methylphenidate Hydrochloride Tablet, Extended Release — Currently in Shortage (presentations listed are 18–72 mg; no 10 or 20 mg presentations), accessed Oct 20, 2026. FDA.
  • American Society of Health-System Pharmacists. Drug Shortage Detail: Methylphenidate Extended Release Oral Presentations. Updated Oct 14, 2026 (Mallinckrodt 10 and 20 mg ER tablets on back order; KVK-Tech 10 and 20 mg ER tablets available). ASHP.
  • Wolraich ML, Hagan JF Jr, Allan C, et al.; American Academy of Pediatrics Subcommittee on Children and Adolescents with ADHD. Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. Pediatrics. 2019;144(4):e20192528. AAP.
  • Centers for Disease Control and Prevention. Clinical Care of ADHD in Children (summary of the AAP guideline; updated Oct 21, 2026). CDC (accessed 2026).
  • Drugs and Lactation Database (LactMed). Methylphenidate. National Institute of Child Health and Human Development; revised Aug 2025. NCBI Bookshelf NBK501310.
  • National Institute for Health and Care Excellence. Attention deficit hyperactivity disorder: diagnosis and management (NG87), 2018, updated 2019; recommendations 1.7.3–1.7.5, 1.7.20–1.7.22, 1.8.6–1.8.7 and 1.10.3. NICE (accessed Oct 2026).
  • Pliszka S, AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007;46(7):894-921. PubMed 17581453.
  • Substance Abuse and Mental Health Services Administration. Key Substance Use and Mental Health Indicators in the United States: Results from the 2023 National Survey on Drug Use and Health (HHS Publication No. PEP24-07-021, NSDUH Series H-59), 2024. SAMHSA (accessed Nov 9, 2026).
  • Drug Enforcement Administration. Adjustment to the Aggregate Production Quota for Methylphenidate (for Sale) for 2023. Federal Register, Oct 3, 2023 (88 FR 68147). Federal Register (accessed Nov 9, 2026).
EDUCATIONAL INFORMATION ONLY. Not medical advice. Graphs are schematic illustrations based on publicly available labeling and are not to clinical scale. Availability status is reviewed periodically and may change. Medication decisions require individualized assessment by a qualified clinician. Brand logos are trademarked; official use requires permission. Full medical disclaimer · Privacy
Back to top